Elig.phs001082.v1.p1.1
Item
*Inclusion:*
boolean
C1512693 (UMLS CUI [1,1])
Elig.phs001082.v1.p1.2
Item
Healthy individuals older than 50 years
boolean
C1708335 (UMLS CUI [1,1])
C0001779 (UMLS CUI [1,2])
Elig.phs001082.v1.p1.3
Item
*Exclusion:*
boolean
C0680251 (UMLS CUI [1,1])
Elig.phs001082.v1.p1.4
Item
History of shingles within 5 years of enrollment
boolean
C0262926 (UMLS CUI [1,1])
C0019360 (UMLS CUI [1,2])
C0332285 (UMLS CUI [1,3])
C0205451 (UMLS CUI [1,4])
C0439234 (UMLS CUI [1,5])
C1516879 (UMLS CUI [1,6])
Elig.phs001082.v1.p1.5
Item
Prior vaccination with Zostavax vaccine for prevention of shingles
boolean
C2368628 (UMLS CUI [1,1])
C1720919 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
Elig.phs001082.v1.p1.6
Item
History of severe allergic reactions to vaccine components, including gelatin and neomycin
boolean
C2106654 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,3])
C1705248 (UMLS CUI [1,4])
C0017237 (UMLS CUI [1,5])
C0027603 (UMLS CUI [1,6])
Elig.phs001082.v1.p1.7
Item
Life-threatening reactions to previous vaccinations
boolean
C1517874 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
Elig.phs001082.v1.p1.8
Item
Adults weighing less than 110 pounds
boolean
C0005910 (UMLS CUI [1,1])
Elig.phs001082.v1.p1.9
Item
Active systemic or serious concurrent illness, including febrile illness on the day of enrollment/vaccination
boolean
C0009488 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0442893 (UMLS CUI [1,3])
C0205404 (UMLS CUI [1,4])
C0221423 (UMLS CUI [1,5])
C0743842 (UMLS CUI [1,6])
C0040223 (UMLS CUI [1,7])
C0042196 (UMLS CUI [1,8])
C1516879 (UMLS CUI [1,9])
Elig.phs001082.v1.p1.10
Item
History of immunodeficiency disorder
boolean
C0262926 (UMLS CUI [1,1])
C0021051 (UMLS CUI [1,2])
Elig.phs001082.v1.p1.11
Item
Chronic HIV, Hepatitis B or Hepatitis C infection
boolean
C0008679 (UMLS CUI [1,1])
C0019693 (UMLS CUI [1,2])
C0019163 (UMLS CUI [1,3])
C0019196 (UMLS CUI [1,4])
Elig.phs001082.v1.p1.12
Item
Known or suspected impairment of immunologic function, including, but not limited to clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
boolean
C0205309 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0004364 (UMLS CUI [1,3])
C0221099 (UMLS CUI [1,4])
C1817756 (UMLS CUI [1,5])
C1512693 (UMLS CUI [1,6])
C2985739 (UMLS CUI [1,7])
C0023895 (UMLS CUI [1,8])
C0011854 (UMLS CUI [1,9])
C0205082 (UMLS CUI [1,10])
C0022658 (UMLS CUI [1,11])
C0205081 (UMLS CUI [1,12])
C0205394 (UMLS CUI [1,13])
C0008679 (UMLS CUI [1,14])
C1444641 (UMLS CUI [1,15])
C1113679 (UMLS CUI [1,16])
C0525058 (UMLS CUI [1,17])
Elig.phs001082.v1.p1.13
Item
Recent or current use of immunosuppressive medication, or anticipated use during study period, including systemic corticosteroids (corticosteroid nasal sprays, inhaled steroids and topical steroids are permissible).
boolean
C0332185 (UMLS CUI [1,1])
C2827774 (UMLS CUI [1,2])
C0021081 (UMLS CUI [1,3])
C3840775 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C0021081 (UMLS CUI [2,3])
C0347984 (UMLS CUI [2,4])
C0008976 (UMLS CUI [2,5])
C1512693 (UMLS CUI [2,6])
C2825233 (UMLS CUI [2,7])
Elig.phs001082.v1.p1.14
Item
Blood pressure >150 systolic or >95 diastolic at Visit 1 12. History of chemotherapy treatment for cancer. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer with recurrence in the past year and any hematologic cancer such as leukemia or lymphoma), which in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol. Prostate cancer may be acceptable if no metastases and not undergoing treatment with immunosuppressive medications.
boolean
C0005823 (UMLS CUI [1,1])
C1320303 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0006826 (UMLS CUI [2,3])
C1707251 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
C1705847 (UMLS CUI [3,3])
C0007117 (UMLS CUI [3,4])
C0553723 (UMLS CUI [3,5])
C1512693 (UMLS CUI [3,6])
C0280100 (UMLS CUI [3,7])
C0678222 (UMLS CUI [3,8])
C0034897 (UMLS CUI [3,9])
C4086728 (UMLS CUI [3,10])
C0376545 (UMLS CUI [3,11])
C0023418 (UMLS CUI [3,12])
C0024299 (UMLS CUI [3,13])
C1444641 (UMLS CUI [3,14])
C1113679 (UMLS CUI [3,15])
C0525058 (UMLS CUI [3,16])
C0600139 (UMLS CUI [4,1])
C3844350 (UMLS CUI [4,2])
C1879533 (UMLS CUI [4,3])
C0445092 (UMLS CUI [4,4])
C0332197 (UMLS CUI [4,5])
C0087111 (UMLS CUI [4,6])
C0021081 (UMLS CUI [4,7])
Elig.phs001082.v1.p1.15
Item
Autoimmune disease, including rheumatoid arthritis, treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel, which in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol (thyroid disease may be acceptable).
boolean
C0004364 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0332293 (UMLS CUI [1,3])
C0021081 (UMLS CUI [1,4])
C0025677 (UMLS CUI [1,5])
C0032952 (UMLS CUI [1,6])
C0699177 (UMLS CUI [1,7])
C0720193 (UMLS CUI [1,8])
C1444641 (UMLS CUI [1,9])
C1113679 (UMLS CUI [1,10])
C0525058 (UMLS CUI [1,11])
C0040128 (UMLS CUI [2,1])
C3844350 (UMLS CUI [2,2])
C1879533 (UMLS CUI [2,3])
Elig.phs001082.v1.p1.16
Item
History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
boolean
C0262926 (UMLS CUI [1,1])
C0018939 (UMLS CUI [1,2])
C0022658 (UMLS CUI [1,3])
C0019045 (UMLS CUI [1,4])
C1514873 (UMLS CUI [1,5])
C0205272 (UMLS CUI [1,6])
C1522577 (UMLS CUI [1,7])
C0019993 (UMLS CUI [1,8])
C0347984 (UMLS CUI [1,9])
C4086728 (UMLS CUI [1,10])
Elig.phs001082.v1.p1.17
Item
Use of anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except aspirin up to 325 mg. daily), Plavix or Aggrenox which may, in the opinion of the investigator, jeopardize volunteer safety or compliance with the protocol.
boolean
C1524063 (UMLS CUI [1,1])
C0003280 (UMLS CUI [1,2])
C0699129 (UMLS CUI [1,3])
C0728963 (UMLS CUI [1,4])
C0085826 (UMLS CUI [1,5])
C0004057 (UMLS CUI [1,6])
C2348070 (UMLS CUI [1,7])
C0633084 (UMLS CUI [1,8])
C0732282 (UMLS CUI [1,9])
C2945640 (UMLS CUI [1,10])
C1113679 (UMLS CUI [1,11])
C0525058 (UMLS CUI [1,12])
Elig.phs001082.v1.p1.18
Item
Receipt of blood or blood products within 6 months prior to enrollment and during the study period
boolean
C0371802 (UMLS CUI [1,1])
C0205452 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.19
Item
Use of antiviral medications within 24 hrs. prior to enrollment, and for the 14 days following study vaccination.
boolean
C1524063 (UMLS CUI [1,1])
C0280274 (UMLS CUI [1,2])
C0439228 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0205448 (UMLS CUI [1,6])
C0439230 (UMLS CUI [1,7])
C0332282 (UMLS CUI [1,8])
C0042196 (UMLS CUI [1,9])
Elig.phs001082.v1.p1.20
Item
Inactivated vaccine within 14 days prior to enrollment and during study period
boolean
C0042212 (UMLS CUI [1,1])
C0205448 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.21
Item
Live, attenuated vaccine within 60 days prior to enrollment and during study period
boolean
C0042211 (UMLS CUI [1,1])
C0205448 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.22
Item
Pregnant or lactating woman, planning to become pregnant (pregnancy should be avoided for 3 months following administration of Zostavax vaccine).
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C2081645 (UMLS CUI [1,3])
Elig.phs001082.v1.p1.23
Item
Use of investigational agents within 30 days prior to enrollment and during study period
boolean
C1524063 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0439231 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.24
Item
Donation of a unit of blood within 6 weeks prior to enrollment and during study period
boolean
C0005794 (UMLS CUI [1,1])
C0205452 (UMLS CUI [1,2])
C0439230 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C1516879 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C2347804 (UMLS CUI [1,7])
Elig.phs001082.v1.p1.25
Item
Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol
boolean
C0004936 (UMLS CUI [1,1])
C0014006 (UMLS CUI [1,2])
C0516937 (UMLS CUI [1,3])
C0332196 (UMLS CUI [1,4])
C0525058 (UMLS CUI [1,5])
Elig.phs001082.v1.p1.26
Item
Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
boolean
C0348080 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C1113679 (UMLS CUI [1,4])
C0683954 (UMLS CUI [1,5])
C1273101 (UMLS CUI [1,6])
C0085732 (UMLS CUI [1,7])
C0525058 (UMLS CUI [1,8])